EP 1242049 A1 20020925 - HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS
Title (en)
HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS
Title (de)
HLA CLASS I A2 TUMOR ASSOZIERTE ANTIGEN PEPTIDE UND IMPFSTOFFE
Title (fr)
COMPOSITIONS DE VACCINS ET PEPTIDES D'ANTIGENE ASSOCIES A UNE TUMEUR DE HLA-A2 DE CLASSE I
Publication
Application
Priority
- US 0034318 W 20001213
- US 17044899 P 19991213
- US 54360800 A 20000405
- US 58320000 A 20000530
Abstract (en)
[origin: WO0141741A1] A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100 % identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
IPC 1-7
IPC 8 full level
A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C07K 19/00 (2006.01)
CPC (source: EP US)
A61K 39/0011 (2013.01 - EP US); A61K 39/001106 (2018.08 - EP US); A61K 39/001151 (2018.08 - EP US); A61K 39/001182 (2018.08 - EP US); A61K 39/001186 (2018.08 - EP US); A61K 39/4615 (2023.05 - EP US); A61K 39/4622 (2023.05 - EP US); A61K 39/464838 (2023.05 - EP US); A61K 45/06 (2013.01 - EP); A61P 35/00 (2018.01 - EP); C07K 14/4748 (2013.01 - EP); C07K 14/705 (2013.01 - EP); C07K 14/70539 (2013.01 - EP); A61K 38/00 (2013.01 - EP); A61K 39/00 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0141741 A1 20010614; WO 0141741 A9 20020530; AU 2273701 A 20010618; CA 2393730 A1 20010614; EP 1242049 A1 20020925; EP 1242049 A4 20050105; JP 2003516344 A 20030513
DOCDB simple family (application)
US 0034318 W 20001213; AU 2273701 A 20001213; CA 2393730 A 20001213; EP 00986510 A 20001213; JP 2001542909 A 20001213